Noopur Raje

44.1k total citations · 6 hit papers
497 papers, 20.3k citations indexed

About

Noopur Raje is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Noopur Raje has authored 497 papers receiving a total of 20.3k indexed citations (citations by other indexed papers that have themselves been cited), including 369 papers in Hematology, 276 papers in Oncology and 248 papers in Molecular Biology. Recurrent topics in Noopur Raje's work include Multiple Myeloma Research and Treatments (365 papers), Protein Degradation and Inhibitors (114 papers) and Peptidase Inhibition and Analysis (81 papers). Noopur Raje is often cited by papers focused on Multiple Myeloma Research and Treatments (365 papers), Protein Degradation and Inhibitors (114 papers) and Peptidase Inhibition and Analysis (81 papers). Noopur Raje collaborates with scholars based in United States, France and Spain. Noopur Raje's co-authors include Kenneth C. Anderson, Teru Hideshima, Paul G. Richardson, Dharminder Chauhan, Nikhil C. Munshi, Klaus Podar, Yu‐Tzu Tai, Sonia Vallet, Steven P. Treon and Constantine S. Mitsiades and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Noopur Raje

480 papers receiving 19.9k citations

Hit Papers

Multiple myeloma 2000 2026 2008 2017 2000 2001 2000 2012 2018 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Multiple myeloma
    2000 1.8k citations Noopur Raje, Kenneth C. Anderson profile →
  2. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
    2001 740 citations Noopur Raje, Teru Hideshima et al. Blood profile →
  3. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
    2000 708 citations Teru Hideshima, Dharminder Chauhan et al. Blood profile →
  4. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
    2012 488 citations Loredana Santo, Teru Hideshima et al. Blood profile →
  5. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study
    2018 307 citations Noopur Raje, Evangelos Terpos et al. profile →
  6. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel
    2023 77 citations Noopur Raje, Kenneth C. Anderson et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Noopur Raje United States 74 12.0k 11.2k 10.1k 2.8k 1.8k 497 20.3k
Sagar Lonial United States 70 12.3k 1.0× 11.9k 1.1× 8.8k 0.9× 2.0k 0.7× 1.6k 0.9× 691 18.9k
Constantine S. Mitsiades United States 68 14.1k 1.2× 9.5k 0.8× 7.3k 0.7× 2.4k 0.9× 1.5k 0.9× 296 20.0k
Robert Z. Orlowski United States 66 13.2k 1.1× 9.7k 0.9× 8.3k 0.8× 1.5k 0.5× 1.4k 0.8× 514 18.6k
Dharminder Chauhan United States 92 19.9k 1.7× 14.9k 1.3× 11.1k 1.1× 3.8k 1.4× 2.3k 1.3× 355 28.2k
Mario Boccadoro Italy 60 8.3k 0.7× 10.9k 1.0× 7.4k 0.7× 2.5k 0.9× 1.7k 1.0× 479 15.9k
Klaus Podar United States 63 8.7k 0.7× 6.6k 0.6× 4.6k 0.5× 1.8k 0.7× 1.3k 0.7× 186 12.8k
Teru Hideshima United States 100 24.6k 2.1× 17.5k 1.6× 13.3k 1.3× 4.6k 1.7× 2.9k 1.7× 472 34.9k
David S. Siegel United States 59 10.1k 0.8× 11.3k 1.0× 7.6k 0.7× 1.2k 0.4× 945 0.5× 415 15.8k
Marina Konopleva United States 94 15.8k 1.3× 15.6k 1.4× 7.9k 0.8× 4.0k 1.4× 2.0k 1.1× 917 30.5k
Irene M. Ghobrial United States 71 8.6k 0.7× 6.5k 0.6× 5.2k 0.5× 2.9k 1.1× 4.1k 2.3× 484 17.1k

Countries citing papers authored by Noopur Raje

Since Specialization
Citations

This map shows the geographic impact of Noopur Raje's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Noopur Raje with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Noopur Raje more than expected).

Fields of papers citing papers by Noopur Raje

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Noopur Raje. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Noopur Raje. The network helps show where Noopur Raje may publish in the future.

Co-authorship network of co-authors of Noopur Raje

This figure shows the co-authorship network connecting the top 25 collaborators of Noopur Raje. A scholar is included among the top collaborators of Noopur Raje based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Noopur Raje. Noopur Raje is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Little, Jessica S, Andrew J. Yee, Omar Nadeem, et al.. (2025). Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy. Blood Advances. 9(16). 4190–4194. 1 indexed citations
2.
Frigault, Matthew J., Jacalyn Rosenblatt, Binod Dhakal, et al.. (2024). Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients With Relapsed and/or Refractory Multiple Myeloma: Results From at Least 1-Year Follow-Up in All Patients. Clinical Lymphoma Myeloma & Leukemia. 24. S237–S237. 2 indexed citations
3.
Martin, Tom, Noopur Raje, Jesús F. San Miguel, et al.. (2024). MM-382 iMMagine-3: A Phase 3, Randomized Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel (Anito-Cel) With Standard of Care in Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 24. S554–S555. 1 indexed citations
4.
Ludwig, Heinz, Nikhil Munshi, Evangelos Terpos, et al.. (2024). Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myeloma. Blood Advances. 8(18). 4979–4982. 5 indexed citations
5.
Berdeja, Jesús G., Min Yang, Noopur Raje, et al.. (2024). Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. Carolina Digital Repository (University of North Carolina at Chapel Hill).
6.
7.
Manier, Salomon, Alexander M. Lesokhin, Mohamad Mohty, et al.. (2023). P870: EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES. HemaSphere. 7(S3). e26808c7–e26808c7. 3 indexed citations
8.
Raje, Noopur, David S. Siegel, Sundar Jagannath, et al.. (2021). Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma (RRMM): Analyses of High-Risk Subgroups in the KarMMa Study. Transplantation and Cellular Therapy. 27(3). S66–S67. 2 indexed citations
9.
Berdeja, Jesús G., Noopur Raje, David S. Siegel, et al.. (2021). Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis. Transplantation and Cellular Therapy. 27(3). S397–S398. 2 indexed citations
10.
Cohen, Adam D., Noopur Raje, Jessica Fowler, et al.. (2019). How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma. Clinical Cancer Research. 26(7). 1541–1554. 82 indexed citations
11.
Ghobrial, Irene M., Ravi Vij, David S. Siegel, et al.. (2019). A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia. Clinical Cancer Research. 25(16). 4907–4916. 39 indexed citations
12.
13.
Yanamandra, Uday, Navin Khattry, Shaji Kumar, et al.. (2017). Consensus in the Management of Multiple Myeloma in India at Myeloma State of the Art 2016 Conference. Indian Journal of Hematology and Blood Transfusion. 33(1). 15–21. 12 indexed citations
14.
Richardson, Paul G., Joseph Mıkhael, Saad Z. Usmani, et al.. (2017). Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 130. 1887–1887. 3 indexed citations
15.
Raje, Noopur, Edward A. Faber, Paul G. Richardson, et al.. (2016). Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research. 22(23). 5688–5695. 22 indexed citations
16.
Bajpai, Richa, Kehinde Adekola, Irawati Kandela, et al.. (2014). Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin. Clinical Cancer Research. 21(5). 1161–1171. 123 indexed citations
17.
Cirstea, Diana, Loredana Santo, Teru Hideshima, et al.. (2014). Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma. Molecular Cancer Therapeutics. 13(11). 2489–2500. 24 indexed citations
18.
Cirstea, Diana, Teru Hideshima, Scott J. Rodig, et al.. (2010). Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by Nanoparticle Albumin-Bound –Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma. Molecular Cancer Therapeutics. 9(4). 963–975. 136 indexed citations
19.
Ooi, Melissa, Patrick Hayden, Vassiliki Kotoula, et al.. (2009). Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib. Clinical Cancer Research. 15(23). 7153–7160. 53 indexed citations
20.
Podar, Klaus, Marc S. Raab, Giovanni Tonon, et al.. (2007). Up-Regulation of c-Jun Inhibits Proliferation and Induces Apoptosis via Caspase-Triggered c-Abl Cleavage in Human Multiple Myeloma. Cancer Research. 67(4). 1680–1688. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sagar Lonial Breakdown of academic impact, for papers by Constantine S. Mitsiades Breakdown of academic impact, for papers by Robert Z. Orlowski Breakdown of academic impact, for papers by Dharminder Chauhan Breakdown of academic impact, for papers by Mario Boccadoro Breakdown of academic impact, for papers by Klaus Podar Breakdown of academic impact, for papers by Teru Hideshima Breakdown of academic impact, for papers by David S. Siegel Breakdown of academic impact, for papers by Marina Konopleva Breakdown of academic impact, for papers by Irene M. Ghobrial
Rankless by CCL
2026